Last reviewed · How we verify
RTA 408 Lotion 0.5%, 1%, 3%
RTA 408 Lotion 0.5%, 1%, 3% is a Small molecule drug developed by Biogen. It is currently in Phase 1 development.
At a glance
| Generic name | RTA 408 Lotion 0.5%, 1%, 3% |
|---|---|
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- RTA 408 Lotion in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RTA 408 Lotion 0.5%, 1%, 3% CI brief — competitive landscape report
- RTA 408 Lotion 0.5%, 1%, 3% updates RSS · CI watch RSS
- Biogen portfolio CI
Frequently asked questions about RTA 408 Lotion 0.5%, 1%, 3%
What is RTA 408 Lotion 0.5%, 1%, 3%?
RTA 408 Lotion 0.5%, 1%, 3% is a Small molecule drug developed by Biogen.
Who makes RTA 408 Lotion 0.5%, 1%, 3%?
RTA 408 Lotion 0.5%, 1%, 3% is developed by Biogen (see full Biogen pipeline at /company/biogen).
What development phase is RTA 408 Lotion 0.5%, 1%, 3% in?
RTA 408 Lotion 0.5%, 1%, 3% is in Phase 1.
Related
- Manufacturer: Biogen — full pipeline
- Compare: RTA 408 Lotion 0.5%, 1%, 3% vs similar drugs
- Pricing: RTA 408 Lotion 0.5%, 1%, 3% cost, discount & access